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A 54-year-old man underwent computed tomography and was suspected of having lung cancer. The patient underwent 
video-assisted thoracoscopic partial lobectomy and was histo-
pathologically diagnosed with small-cell lung cancer. For the 
treatment of the residual tumor, including the metastatic medi-
astinal lymph nodes, he subsequently received chemoradio-
therapy combined with chemotherapy (cisplatin and etoposide) 
and radiotherapy at a total dose of 60 Gy delivered in 30 frac-
tions. The patient was successfully treated and had a complete 
response. However, at 4 months after surgery, blurred vision 
was evident in the right eye; a mass measuring 5 mm in size was 
observed in the right iris using slit lamp microscopy. No abnor-
malities were found in the ocular fundus, including the retina, 
and ocular tension. The corrected visual acuity was measured 
at 0.9 in the visual acuity test using the Landolt ring chart; this 
corresponded to 18 of 20 in the Snellen chart. The patient was 
diagnosed with iris metastasis. No other diseases were detected 
on chest and abdominal computed tomography, head magnetic 
resonance imaging, and bone scintigraphy. Subsequently, che-
motherapy with cisplatin and etoposide was administered. The 
metastatic tumor exhibited a transient reduction in size but then 
regrew. Consequently, the patient received radiotherapy with 
7-MeV electrons through an anterior port for treatment of the 
iris metastasis. Because the patient was treated with radiotherapy 
without computed tomography simulation, for reference, dose 
distribution curves obtained using a representative radiotherapy 
simulation model are shown in Fig. 1. Daily fraction size was 
2 Gy, 5 days per week, and the total dose was 40 Gy delivered 
in 20 fractions. A bolus with a 5 mm water-equivalent thickness 
was used to compensate for the surface dose in the tumor. The 
overall treatment time was 30 days. The tumor volume decreased 
rapidly after the initiation of radiotherapy and had completely 
disappeared by the completion of treatment (Fig. 2). Regarding 
acute toxicities, the patient had mild radiation keratitis, conjunc-
tivitis, and dermatitis; however, these reactions had all resolved 
shortly after the completion of radiotherapy.
COMMENTS
During the clinical course of cancer patients rarely expe-
rience uveal metastasis. Among uveal metastases, almost 90% 
are accounted for by choroidal metastasis; iris metastasis is 
an extremely rare presentation with an incidence of less than 
10%.1 There have been few reports regarding cases of distant 
metastasis that have occurred exclusively in the iris. Among iris 
tumors, primary melanoma accounts for almost 50% and meta-
static tumors approximately 20%.2 Of the primary tumors from 
which iris metastases originate, lung cancer is the second most 
common malignancy next to breast cancer; these two cancers 
account for two-thirds of all primary tumors.1,3 Iris metasta-
sis can cause various symptoms, including blurred vision and 
visual field defects, and in some patients secondary glaucoma 
because of angle closure. Surgery (enucleation) and chemo-
therapy have been used for the treatment of iris metastasis 
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FIGURE 1.  Photograph of a computed tomography slice 
showing the isodose distribution in the right eye using a 
radiotherapy simulation model. Electron beams are delivered 
through an anterior port to the iris, which is homogeneously 
encompassed within the 100% dose level. The radiation 
dose to the ocular fundus is reduced to less than 50% of the 
prescribed dose because of rapid dose falloff.
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with palliative intent. Usually, surgical procedures such as 
enucleation are considered as being unfavorable for palliative 
care, and less invasive treatments are considered more favor-
able. From the point of view of systemic disease with distant 
metastasis, chemotherapy is generally considered to be the first 
choice in the treatment of iris metastasis. However, in the pres-
ent case, chemotherapy was ineffective for the control of iris 
metastasis and accordingly radiotherapy was given. To date, 
there have been few studies that have reported on the outcome 
of radiotherapy for iris metastasis. Generally, palliative radio-
therapy regimens are completed within a short period using low 
radiation doses, because patients with distant metastasis have 
a poor prognosis with regard to survival. Indeed, the median 
survival time for patients with iris metastasis from lung cancer 
is reported to be only 4 months.3 However, our patient exhibited 
good tumor control with the exception of iris metastasis and 
was expected to have a long survival time. Therefore, a rela-
tively high radiation dose was delivered in conventional frac-
tions. Although the optimal radiation dose for this disease is 
unclear at this stage, the present total dose of 40 Gy may be 
sufficient to control the metastatic tumor from small-cell lung 
cancer, because it is a relatively radiosensitive tumor. In addi-
tion, electrons were used for radiotherapy in the current study. 
Relative to photons (x-rays), the use of electrons in radiotherapy 
can considerably reduce the radiation dose and treatment vol-
ume regarding the retina. This is because electron beams exhibit 
a rapid dose falloff relative to photon beams. Although the tol-
erance dose for the retina is generally estimated to be approxi-
mately 50 Gy, when delivered in conventional fractions, it has 
been reported that even a dose of less than or equal to 40 Gy can 
cause severe retinopathy.4,5 Accordingly, the use of electrons in 
the treatment of iris metastasis is considered as being a safer 
approach. This treatment appeared to contribute to an improve-
ment in the patient’s quality of life because of effective control 
of the metastatic tumor in the iris.
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FIGURE 2.  Photographs of the site 
of the metastatic tumor derived from 
small-cell lung cancer in the iris of 
the right eye, (A) before and (B) at 
the completion of radiotherapy. The 
metastatic tumor had completely 
disappeared after treatment and only 
residual pigmentation remained.
